{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/mitigating-study-start-risks-biotechs-early-phase-immuno-oncology-study#webpage",
"url": "https://www.fortrea.com/insights/mitigating-study-start-risks-biotechs-early-phase-immuno-oncology-study",
"name": "Mitigating study start-up risks in a biotech's early phase immuno-oncology study",
"description": "This Fortrea case study examines how an early-phase immuno-oncology clinical trial overcame significant study start-up risks following the rejection of a regulatory submission for a genetically modified organism (GMO) investigational medicinal product. A biotech sponsor developing a treatment for patients with advanced solid tumors encountered a five-and-a-half-month setback when insufficient manufacturing testing led to regulatory rejection of the initial submission. To recover the program, Fortrea collaborated closely with the sponsor to provide regulatory guidance, define a clear resubmission pathway, establish realistic approval timelines, maintain site engagement, and align stakeholder expectations throughout the delay period. Through proactive risk mitigation, operational planning, and continuous communication with study sites, the team preserved trial readiness and positioned the program for rapid activation once approval was secured. The strategy enabled successful regulatory resubmission within approximately three months, regulatory approval roughly 2.5 months later, and accelerated patient enrollment following approval, helping the sponsor maintain momentum in its Phase I/Ib immuno-oncology development program."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Mitigating study start-up risks in a biotech's early phase immuno-oncology study",
"item": "https://www.fortrea.com/insights/mitigating-study-start-risks-biotechs-early-phase-immuno-oncology-study"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/mitigating-study-start-risks-biotechs-early-phase-immuno-oncology-study#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/mitigating-study-start-risks-biotechs-early-phase-immuno-oncology-study#webpage"
},
"headline": "Early-Phase Immuno-Oncology Study Risk Mitigation: Managing Regulatory Delays and Trial Start-Up Risks | Fortrea Case Study",
"description": "This Fortrea case study examines how an early-phase immuno-oncology clinical trial overcame significant study start-up risks following the rejection of a regulatory submission for a genetically modified organism (GMO) investigational medicinal product. A biotech sponsor developing a treatment for patients with advanced solid tumors encountered a five-and-a-half-month setback when insufficient manufacturing testing led to regulatory rejection of the initial submission. To recover the program, Fortrea collaborated closely with the sponsor to provide regulatory guidance, define a clear resubmission pathway, establish realistic approval timelines, maintain site engagement, and align stakeholder expectations throughout the delay period. Through proactive risk mitigation, operational planning, and continuous communication with study sites, the team preserved trial readiness and positioned the program for rapid activation once approval was secured. The strategy enabled successful regulatory resubmission within approximately three months, regulatory approval roughly 2.5 months later, and accelerated patient enrollment following approval, helping the sponsor maintain momentum in its Phase I/Ib immuno-oncology development program.",
"genre": "Case Study",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2026-05/immuno-oncology-startup-risk.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2026-05-06",
"dateModified": "2026-05-06",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2026-05/early-phase-study-risk-mitigation.pdf",
"encodingFormat": "application/pdf"
}
}
]
}